New Omega-3 Supplement Launches in Las Vegas
The new supplement uses a specialized delivery system to potentially increase fatty acid absorption for users.
Updated on Oct. 26, 2026 in Alzheimer’s
Live Poll
Is now a good time to pay more for supplements promising better nutrient absorption?
SourceOne Global Partners launched LysOmega, a new omega-3 supplement, at the SupplySide Global 2026 event in Las Vegas. The product aims to improve nutrient delivery to the brain and eyes for individuals interested in supplemental health.
Why it matters
Optimal organ absorption of DHA and EPA remains a challenge for many, and this new formulation seeks to address those limitations through a specialized delivery system. The development follows a four-year research project and sets the stage for upcoming human clinical trials.
A Phase I human pharmacokinetic study demonstrated that the VESIsorb delivery system increases omega-3 absorption by up to 26-fold. The effectiveness of this formulation for achieving higher circulating DHA and EPA levels in humans remains under investigation.
The players
SourceOne Global Partners
A developer of health and wellness products focused on nutrient delivery systems.
Michael Davidson
A researcher and clinical trial lead for the planned LysOmega study.
The details
LysOmega combines DHA and EPA from fish oil with phospholipids and choline. It utilizes the VESIsorb delivery system, which has been in commercial use for 35 years and relies on small droplet sizes to enable better bioavailability and homogeneity. This process is designed to help fatty acids cross the blood-brain and blood-retina barriers more effectively.
Timeline
October 26-30, 2026: SupplySide Global 2026 held in Las Vegas.
Q4 2026: Planned commencement of human clinical trials.
Health Landscape
The supplement industry continues to iterate on delivery technologies like the VESIsorb system to overcome traditional hurdles in nutrient bioavailability. This launch follows a four-year development cycle aimed at improving how essential fatty acids are absorbed by the brain and eyes.
Those considering new omega-3 supplements for brain or eye health should note that human clinical data on this specific formulation is still forthcoming. It is worth discussing any changes to your wellness regimen with your doctor to ensure they align with your health needs.
The takeaway
While the VESIsorb system has a long track record of commercial use, the specific clinical impact of LysOmega is currently being evaluated for future trials. Track the outcomes of planned clinical studies to understand how this formula compares to standard omega-3 supplements.
What happens next
A human clinical trial evaluating the formulation is scheduled to commence in Q4 2026.
Further reading
For more information on current brain health research, visit Alzheimer’s.
Source note: This article includes information reported by Nutritioninsight.
Live Poll
Is now a good time to pay more for supplements promising better nutrient absorption?
